Table 2 

Relationship analysis between positive rate of XIAP/Smac and clinicopathologic variables 

n* 
XIAPC 
Smac 
XIAPN 





PR 
P value 
PR 
P value 
PR 
P value 



Age 

<50 
49 
42(85.7%) 
20(40.8%) 
21(42.9%) 

≥50 
53 
0.789 
0.145 
1.000 

Size 
44(83.0%) 
14(26.4%) 
23(43.4%) 

≤5 cm 
77 
67(87.0%) 
26(33.8%) 
33(42.9%) 

>5 cm 
25 
19(76.0%) 
0.212 
8(32.0%) 
1.000 
11(44.0%) 
1.000 
LN status 

N_{0} 
39 
33(84.6%) 
14(35.9%) 
14(35.9%) 

N_{13} 
63 
53(84.1%) 
1.000 
20(31.7%) 
0.672 
30(47.6%) 
0.305 
Grade 

I 
25 
22(88.0%) 
10(40.0%) 
13(52.0%) 

IIIII 
77 
64(83.1%) 
0.755 
24(31.2%) 
0.468 
31(40.3%) 
0.356 
ER 

positive 
39 
31(79.5%) 
14(35.9%) 
20(51.3%) 

negative 
63 
55(87.3%) 
0.401 
20(31.7%) 
0.672 
24(38.1%) 
0.221 
PR 

positive 
44 
36(81.8%) 
18(40.9%) 
23(52.3%) 

negative 
58 
50(86.2%) 
0.591 
16(27.6%) 
0.204 
21(36.2%) 
0.112 
HER2 

positive 
94 
78(83.0%) 
34(36.2%) 
41(43.6%) 

negative 
8 
8(100.0%) 
0.351 
0(0.0%) 
0.049 
3(37.5%) 
1.000 
XIAPN 

positive 
44 
41(93.2%) 
16(36.4%) 
/ 

negative 
58 
44(75.9%) 
0.030 
18(31.0%) 
0.672 
/ 



n*: number of cases. PR: positive rate. LN: lymph node. XIAPC and XIAPN denoted cytoplasmic immune staining score and nuclear labeling of XIAP, respectively. Pvalues (two sided) < 0.05 were highlighted in bold. 

Zhang et al. Diagnostic Pathology 2011 6:49 doi:10.1186/17461596649 